Izilox

Moxifloxacin, the active ingredient in Izilox, is a Fluoroquinolone presented as an injection solution for intravenous use. It treats serious bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, skin and soft tissue infections, and complicated intra‑abdominal infections in adult patients.

GNH USA supplies Izilox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Moxifloxacin is a fluoroquinolone antibacterial indicated for several serious bacterial infections.

- Community‑acquired bacterial pneumonia: provides rapid bacterial eradication and clinical improvement. - Acute bacterial sinusitis: resolves sinus infection symptoms and clears pathogenic organisms. - Skin and soft tissue infections: treats complicated cellulitis and wound infections caused by susceptible bacteria. - Complicated intra‑abdominal infections: targets mixed aerobic and anaerobic pathogens to control intra‑abdominal sepsis.

Adverse reactions may occur with any antibacterial therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, occasionally watery. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness. - Rash: mild skin erythema or pruritus. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur without warning. - QT interval prolongation: risk of cardiac arrhythmias. - Clostridioides difficile infection: severe colitis after antibiotic exposure. - Severe allergic reactions: anaphylaxis, angioedema. - Hepatic failure: rare but potentially life‑threatening liver injury. - Anaphylactic shock: immediate hypersensitivity requiring emergency care.

Use of Izilox requires careful clinical assessment and monitoring.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution; observe liver function tests. - Concomitant QT‑prolonging drugs: assess cardiac risk and monitor ECG. - History of tendon disorders: avoid use due to increased rupture risk. - Pregnancy and lactation: safety not established; prescribe only if benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Other fluoroquinolones: additive toxicity. - Antacids containing magnesium or aluminum: reduce absorption. - Cyclosporine: increased serum levels and nephrotoxicity. - Warfarin: enhanced anticoagulant effect, risk of bleeding. - Theophylline: elevated plasma concentrations, risk of toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened CNS stimulation. - Diuretics (especially thiazides): potential hypoglycemia. - Corticosteroids: increased risk of tendon rupture.